YieldMax COIN Option Income Strategy ETF vs Hims and Hers Health Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.66 (market cap $384.59M), while Hims and Hers Health Inc trades at $28.41 (market cap $6.89B). The key difference: Hims and Hers Health Inc is far larger — about 17.9× YieldMax COIN Option Income Strategy ETF's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Hims and Hers Health Inc for 21 Days on average.
| CONY | HIMS | |
|---|---|---|
Market Cap | $384.59M | $6.89B |
Volume | 792,653 | 5,446,628 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $62.76 |
52-Week Low | $17.73 | $14.52 |
Typical Hold Time | 41 Days | 21 Days |
Enterprise Value | — | $7.60B |
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →